Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets.
BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
| Date | Monday, November 15, 2021 |
| Time | 4:30 p.m. ET |
| Toll free (U.S.) | (866) 672-5029 |
| International | (409) 217-8312 |
| Conference ID | 57399556 |
| Webcast (live and replay) | www.osmotica.com under the “Investor & News” section |
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ®.
Osmotica has operations in the United States and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
